Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.

被引：0
|
作者：
Hobart, J. [1 ,2 ]
Ziemssen, T. [3 ]
Feys, P. [4 ]
Linnebank, M. [5 ]
Goodman, A. [6 ]
Farrell, R. [7 ]
Englishby, V. [8 ]
McNeill, M. [8 ]
Chang, I. [9 ]
Mehta, L. [9 ]
Elkins, J. [9 ]
机构：
[1] Plymouth Univ, Peninsula Sch Med, Plymouth Hosp NHS Trust, Plymouth, Devon, England
[2] Plymouth Univ, Peninsula Sch Dent, Plymouth Hosp NHS Trust, Plymouth, Devon, England
[3] Univ Clin Dresden, Dresden, Germany
[4] Univ Hasselt, Diepenbeek, Belgium
[5] Univ Zurich Hosp, Zurich, Switzerland
[6] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[7] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, London, England
[8] Biogen, Maidenhead, Berks, England
[9] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
254
引用
收藏
页码：833 / 834
页数：2
相关论文
共 50 条
  • [21] Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study
    Valet, Maxime
    El Sankari, Souraya
    Van Pesch, Vincent
    Detrembleur, Christine
    Lejeune, Thierry
    Stoquart, Gaetan
    CLINICAL BIOMECHANICS, 2021, 86
  • [22] Prolonged-release fampridine as adjunct therapy to active enabled motor training in multiple sclerosis patients: a pilot, double-blind, placebo-controlled study
    Jacques, F.
    Schembri, A.
    Nativ, A.
    Paquette, C.
    Kalinowski, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 673 - 673
  • [23] USTEKINUMAB RESULTS: IN RAPID, SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PHYSICAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS: FROM A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL
    Kavanaugh, A.
    Menter, A.
    Han, C.
    Mendelsohn, A.
    Schenkel, B.
    Gottlieb, A.
    VALUE IN HEALTH, 2009, 12 (07) : A524 - A524
  • [24] Treatment of fatigue in multiple sclerosis: a phase II double-blind, randomized, mono-center, placebo-controlled crossover-sub-study on prolonged-release fampridine
    Weller, D.
    Sutter, T.
    Koeszeghi, L.
    Kapitza, S.
    Reuter, K.
    Filli, L.
    Zoerner, B.
    Farkas, M.
    Weller, M.
    Linnebank, M.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 526 - 526
  • [25] Sustained Release Fampridine Improves Walking Speed across a Wide Range of Baseline Deficits: Pooled Data from Three Placebo-Controlled Studies in Patients with Multiple Sclerosis
    Edwards, Keith
    Brown, Theodore
    Schapiro, Randall
    Goodman, Andrew
    Marinucci, Lawrence
    Cohen, Ron
    Blight, Andrew
    NEUROLOGY, 2010, 74 (09) : A565 - A565
  • [26] The effect of prolonged-release fampridine on cognitive performance, fatigue, depression and quality of life of MS patients: results from the Ignite study
    Bakirtzis, C.
    Konstantinopoulou, E.
    Minti, F.
    Mandoras, N.
    Nikolaidis, I.
    Tatsi, T.
    Afrantou, T.
    Ioannidis, P.
    Grigoriadis, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 291 - 291
  • [27] Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study
    Roeth, Alexander
    Broome, Catherine M.
    Barcellini, Wilma
    Jilma, Bernd
    Hill, Quentin A.
    Cella, David
    Tvedt, Tor Henrik Anderson
    Yamaguchi, Masaki
    Lee, Michelle
    Shafer, Frank
    Wardecki, Marek
    Jiang, Xiaoyu
    Patel, Parija
    Joly, Florence
    Weitz, Ilene C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (03) : 280 - 288
  • [28] The effect of prolonged-release fampridine treatment on health-related quality of life outcomes after 1 year: results from the ENABLE study
    Sorensen, P. S.
    Macdonell, R.
    Pozzilli, C.
    Nagels, G.
    Laplaud, D.
    de Jong, B.
    Silva, A. M.
    Nicholas, R.
    Gaebler, J. A.
    Agarwal, S.
    Wang, P.
    JOURNAL OF NEUROLOGY, 2014, 261 : S137 - S138
  • [29] Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
    Giovanni Castelnovo
    Oliver Gerlach
    Mark S. Freedman
    Arnfin Bergmann
    Vladimiro Sinay
    Tamara Castillo-Triviño
    George Kong
    Thijs Koster
    Heather Williams
    Arie R. Gafson
    Joep Killestein
    CNS Drugs, 2021, 35 : 1009 - 1022
  • [30] Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
    Castelnovo, Giovanni
    Gerlach, Oliver
    Freedman, Mark S.
    Bergmann, Arnfin
    Sinay, Vladimiro
    Castillo-Trivino, Tamara
    Kong, George
    Koster, Thijs
    Williams, Heather
    Gafson, Arie R.
    Killestein, Joep
    CNS DRUGS, 2021, 35 (09) : 1009 - 1022
12345